Movement Disorder Society Unified Parkinson’s Disease Rating Scale Motor Examination Retains Its 2-Domain Profile in Both On and Off States
Objective: This study aims to validate the two-domain structure of MDS-UPDRS Part III items in both medication states, exploring the discriminative ability of the tremor…Responders to a Highly Challenging Balance and Gait Intervention in People with Parkinson’s Disease
Objective: To characterize responsiveness to a highly challenging balance and gait intervention (HiBalance) in participants with Parkinson's disease (PD). Background: Exercise potentially improves gait, balance,…An Innovative Approach Combining Transcranial Direct Current Stimulation and Speech Therapy for the Treatment of Dysphagia in Parkinson’s Disease.
Objective: Our study used a combined approach based on non-invasive neuromodulation and speech therapy to improve dysphagia in PD patients. Background: Dysphagia is one of…Breaking Barriers to Offer Evidence-Based Services for Patients with Parkinson’s Disease in South Africa
Objective: To provide evidence-based services for patients with Parkinson’s disease considering the burden of disease in South Africa (SA) and access, socio economic and technology…Quality of life assessment in patients with Parkinson’s disease
Objective: The objective of the study was to assess the quality of life in patients with Parkinson's disease (PD) and to establish statistical correlations with…A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.
Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial
Objective: The OASIS exploratory trial aimed to evaluate the effects of opicapone (OPC) on sleep disorders in Parkinson’s disease (PD) patients with motor fluctuations (MF)…Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612
Objective: Characterize dopaminergic treatment-emergent adverse events (TEAEs) reported with 24h ND0612 treatment in clinical studies. Background: Dopaminergic adverse events are commonly reported across the spectrum…Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study
Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience
Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 436
- Next Page »